Background and aims Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Enforcement of universal screenings would easily prevent sickness, expenses and death but enforcement isn’t easy.

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...

Pooled data show that no or shorter antibiotic prophylaxis for upper GI bleeding in cirrhosis is very likely noninferior to longer courses for all-cause mortality, challenging long-standing advice.

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...